Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Exemestane and MK-2866 Interaction: Avoid | Peptide Database

Compound Profiles Exemestane Steroidal Aromatase Inhibitor | Irreversible Estrogen Control Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Exemestane with MK-2866?

Combining Exemestane with MK-2866 is not recommended. Both Exemestane and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Exemestane and MK-2866 safe together?

This combination carries significant risk. Both Exemestane and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Exemestane and MK-2866?

Both Exemestane and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Exemestane and MK-2866?

Exemestane has a half-life of ~24 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Superdrol produces substantial lean mass gains in compressed timeframes, typically 8-12 pounds of lean tissue in a 3-4 week cycle. These gains are notably dry and devoid of water retention due to the absence of estrogenic activity. Widely reported to produce some of the most dramatic strength increases of any oral steroid. Users commonly report significant personal records within the first 2-3 weeks of use. As a non-aromatizing DHT derivative, Superdrol promotes a dense, dry, and grainy muscular appearance without subcutaneous water retention. Often used in the final weeks before a bodybuilding competition.

Source: peptide-db.com ↗

Research Indications

Restores reproductive hormone secretion in functional or congenital cases by stimulating dormant GnRH axis. Triggers oocyte maturation with 45% live birth rate and zero severe OHSS cases; safer than hCG. Restores reproductive hormone pulsatility in women with hypothalamic amenorrhea. Modulates sexual brain processing; increases penile tumescence by 56% vs placebo. Modulates sexual and attraction brain processing; increases self-reported sexiness. Preclinical evidence suggests influence on energy expenditure and activity levels.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Meldonium is primarily administered orally in capsule form. Standard pharmaceutical preparations (Mildronate) are available as 250 mg and 500 mg capsules. The drug has good oral bioavailability and reaches peak plasma concentrations within 1-2 hours of ingestion. Its relatively short half-life of 4-6 hours means some protocols split the daily dose into two administrations, though once-daily dosing is also common. An intravenous formulation exists and is used in clinical settings for acute cardiac events, but oral administration is the standard route for all performance enhancement and chronic use applications. Cardioprotection (On-Cycle Support) 500 mg/day Once daily or split into two doses (250 mg twice daily) Oral (capsule) Clinical Dose (Ischemic Heart Disease) 500-1000 mg/day Once daily or split into two doses

Source: peptide-db.com ↗
Side effects

Common Side Effects

Hot flashes and increased sweating Leg cramps and muscle spasms Joint pain or stiffness Peripheral edema (mild swelling in extremities) Flu-like symptoms during initial weeks

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides